Ticker ATNX – Athenex – sales, description, marketcap – Tickerday.com

ATNX

Athenex

–

Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;

Marketcap: 999.50M; Volume: 143.67K; AvgVol 3m: 811.06K; Beta: –;

Cost estimate:

P/E: –; EPS: -1.46; EPS growth quarter/prev quarter: -13.20%;

EPS growth this year: 8.10%; EPS growth past 5 years: -39.10%;

EPS ttm: -1.46;

P/S: 08.04; P/B: 7.20; P/Cashflow: 9.74; P/FCF: ;

Sales: 140.83M; Sales growth quarter/prev quarter: 81.10%; Sales growth past 5 years: 142.30%;

Profitability:

Gross Margin: 39.40%; Profit Margin: -82.60%; Operating Margin: -78.10%;

ROA – return on assets: -39.00%; ROE – return on equity: -72.20%; LT Debt/Equity: 0.68; Total Debt/Equity: 0.69;

Dividend: –; Dividend Yield (%): –;

Insider Ownership: 7.10%; Insider Transactions:47.07%;

Institutional Ownership: 50.80%; Institutional Transactions: -1.42%;

Data update: 07/10/2020.